Medicine Information

eporise

Name: eporise
Brand: eporise
Rating: 4.5 (117 reviews)

Injection3000 IUErythropoiesis-Stimulating Agents (ESAs)ATC: B03XA01

Generic Name

Epoetin Alfa 3000 IU Injection

Manufacturer

Various

Country

Global

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
eporise 3000 iu injection	৳ 1,400.00	N/A

Description

Overview of the medicine

Epoetin alfa is a recombinant human erythropoietin that stimulates red blood cell production. It is used to treat anemia associated with chronic kidney disease, chemotherapy, and certain surgical procedures.

Uses & Indications

Anemia associated with Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.

Anemia in cancer patients receiving myelosuppressive chemotherapy.

Anemia in zidovudine-treated HIV-infected patients.

Reduction of allogeneic red blood cell transfusions in surgery patients at high risk of blood loss.

Dosage

Adults

Dosage is highly individualized based on patient's condition, hemoglobin target, and route of administration (IV or SC). For CKD, typically 50-100 IU/kg 3 times/week initially. For chemotherapy-induced anemia, 150 IU/kg 3 times/week or 40,000 IU once weekly SC.

Elderly

No specific dose adjustment required, but start with lower doses and monitor closely.

Renal_impairment

Primary indication; dosage adjusted based on hemoglobin response and clinical need.

How to Take

Administer by intravenous (IV) or subcutaneous (SC) injection. Do not shake the vial or syringe. Follow aseptic technique. For self-administration, patients should be trained by a healthcare professional.

Mechanism of Action

Binds to erythropoietin receptors on erythroid progenitor cells, stimulating their proliferation and differentiation, leading to increased red blood cell production.

Pharmacokinetics

Onset

Significant increase in hemoglobin levels typically seen within 1-2 weeks.

Excretion

Mainly through renal excretion and bile, with some degradation by erythroid cells.

Half life

Intravenous: 4-13 hours; Subcutaneous: 12-24 hours.

Absorption

Subcutaneous absorption is slower and more sustained than intravenous administration.

Metabolism

Primarily hepatic, but also renal and through erythroid cells.

Side Effects

Contraindications

Uncontrolled hypertension.
Pure Red Cell Aplasia (PRCA) following prior epoetin treatment.
Known hypersensitivity to epoetin alfa, albumin (human), or any excipients.
Patients undergoing major surgery who cannot receive adequate antithrombotic prophylaxis.

Drug Interactions

Iron supplements

Epoetin alfa requires adequate iron stores for optimal effect; iron supplementation is often necessary.

Other hematologic agents

No significant direct drug-drug interactions reported, but concurrent use of other agents affecting erythropoiesis should be monitored.

Storage

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Do not shake.

Overdose

Overdose can lead to polycythemia (excessively high red blood cell count). In severe cases, phlebotomy (blood letting) may be required to reduce blood viscosity. Contact a healthcare professional immediately.

Pregnancy & Lactation

Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Epoetin alfa is excreted in breast milk; exercise caution when administering to a nursing mother.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

1 pre-filled syringe of 3000 IU/0.3mL1 vial of 3000 IU/mL

Shelf Life

Typically 24 to 36 months from manufacturing date.

Availability

Pharmacies, Hospitals

Approval Status

Approved

Patent Status

Off-patent (Generic available)

WHO Essential Medicine

Yes

Clinical Trials

Epoetin alfa has undergone extensive clinical trials demonstrating its efficacy and safety in various indications, particularly in the management of anemia associated with chronic kidney disease and chemotherapy.

Lab Monitoring

Hemoglobin and hematocrit levels (regularly)
Blood pressure (regularly)
Serum ferritin and transferrin saturation (for iron status)
Renal function tests

Doctor Notes

Closely monitor hemoglobin levels and adjust dose to maintain levels within target range (e.g., 10-11 g/dL). Avoid exceeding 11 g/dL.
Ensure adequate iron stores before and during epoetin alfa therapy. Iron supplementation is usually required.
Monitor blood pressure frequently, especially at the initiation of therapy and during dose adjustments. Manage hypertension promptly.
Educate patients on the signs and symptoms of serious side effects, including thromboembolic events and potential for tumor progression.

Patient Guidelines

Do not shake the medicine; this can damage the active ingredient.
Store refrigerated between 2°C to 8°C and protect from light.
Report any unusual side effects or symptoms, especially sudden chest pain or vision changes.
Ensure regular monitoring of blood pressure and blood tests as advised by your doctor.

Missed Dose Advice

If a dose is missed, take it as soon as you remember, unless it is almost time for your next dose. Do not double the dose. Contact your doctor or nurse for advice.

Driving Precautions

Epoetin alfa generally does not impair the ability to drive or operate machinery. However, if you experience side effects like headache or seizures, avoid such activities.